Benchling as System Software for Biologics

This is why Benchling looks less like a generic lab notebook and more like system software for biologics R&D. Small molecule drug teams mostly track fixed chemical structures, while biologics teams must track sequences, variants, parent child lineage, batches, aliquots, assay results, and storage location across DNA, RNA, proteins, antibodies, and cell lines. Benchling built product modules around exactly that workflow, from sequence design to registry to inventory.

• The core technical difference is that biologics are large, heterogeneous products derived from living systems, not cleanly defined chemical compounds. That makes characterization and manufacturing control harder, which is why teams need software that stores context around each construct and process step, not just a final compound record.
  3 fda 4 fda
• Benchling productized that complexity with molecular biology tools for DNA, RNA, and amino acid design, a registry that links plasmids, proteins, antibodies, and modified sequences, and inventory that ties physical samples and labels back to notebook entries. In practice, that lets a scientist trace one failed assay back to the exact construct, batch, and storage container used.
  1 benchling 2 benchling 5 sacra
• That workflow fit the rise of CRISPR, gene therapy, and cell therapy, where labs moved from one off academic experiments to repeatable industrial programs. Benchling then expanded from individual scientist usage into larger enterprise deals, with 43% of new revenue in 2021 coming from top 50 biopharmas, up from 23% in 2019.
  5 sacra 6 sacra

The next phase is deeper entrenchment across the biologics stack. As more drug programs depend on sequence aware design, lineage tracking, and audit ready sample records, the winning software layer will sit between discovery and manufacturing. That pushes Benchling toward larger platform deals, because replacing the system that holds a lab's molecular memory gets harder over time.